SPECIAL FEATURE
Innovative
University of Cincinnati Program
Trains
Next Generation of
Pharmaceutical Professionals
University of Cincinnati program
fills
need for cross-disciplinary training
In
2008, global pharmaceutical sales
topped $773 billion, according to
IMS Health, the world's leading
provider of market intelligence to
the pharmaceutical and health care
industries. While 2009 statistics
are still rolling in, IMS predicts
global pharmaceutical sales will
grow 4.5 to 5.5 percent in 2009,
possibly surpassing $820 billion.
With pharmaceutical products ranking
among the top three most profitable
industries in the United States
(according to the Fortune 500), the
need for qualified candidates with
cross-disciplinary training in all
aspects of drug development is no
longer a "wishful thinking"
scenario, but a necessity.
"There has been a surge in global
drug discovery and development
efforts, a fact that is supported by
the uptick in global pharmaceutical
sales," says Pankaj Desai, PhD, a
faculty member of the University of
Cincinnati (UC) James L. Winkle
College of Pharmacy. "The drug
industry needs visionary people who
are able to speak the same language
across the globe and see the big
picture."
According to Desai, few
professionals have a formal
education in all of the diverse
activities needed to take a
therapeutic solution from concept to
patient bedside. Most of the
pharmaceutical industry's research,
testing, marketing and sales
professionals are trained in the
silo in which their job function
exists. But in today's global
economy, it is important for project
leaders to comprehend the
multidisciplinary nature of drug
development.
That's why, five years ago, the
University of Cincinnati introduced
a master's degree program through
its college of pharmacy. The
university's master of science in
pharmaceutical sciences with
specialization in drug development
offers a unique collaboration of
academia, industry and government.
The program is designed to give
students a 30,000 foot view of the
drug industry as a whole, filling
the need for cross-disciplinary
training in scientific and
regulatory aspects of drug
development.

Pictured from left to right are Drs.
Kevin Skare, William Sietsema,
Pankaj Desai (faculty) with Lindsay
Boeing and Dr. Brenna Carey
(students).
Though still considered relatively
young, the drug development program
has been met with critical acclaim
from well-respected experts in the
pharmaceutical industry. Dr. William
Sietsema, vice president of U.S.
Regulatory Consulting & Submissions
for Kendle International
¾
one of the world's leading clinical
research organizations
¾
says the program improves his
company's talent base and helps
Kendle associates progress in their
careers.
"The drug development program at UC
provides exactly the sort of
cross-disciplinary training that is
needed in our industry. Graduates of
the program are attractive to the
pharmaceutical industry because of
their broad understanding of the
development process and strategies
for speeding new products to market.
Until this program was developed,
these were not skills that could be
learned in a classroom, they could
only be attained through on-the-job
experience," said Sietsema, who is
also an adjunct professor at the
Winkle College of Pharmacy.
The program's unique curriculum is
what separates the UC program from
others. It was developed with close
collaborations between Desai, who
now serves as director of the
program, UC's Academic Health
Center, Cincinnati Children's
Hospital Medical Center, regional
pharmaceutical companies and
clinical research organizations.
"The curriculum covers all aspects
of drug development, from
synthesizing compounds and clinical
trials, to medical devices, to
market launch and regulatory
compliance," he says. "Each course
is designed to introduce students to
one specific aspect of drug
development. To my knowledge, there
is no other academic program that
provides the same depth and breadth
of information that this master's
program does."
Faculty members include recognized
industry experts from companies such
as Procter & Gamble, Kendle
International and Meridian
Biosciences, as well as professors
from the Winkle College of Pharmacy
and College of Medicine at the
University of Cincinnati.
"Having faculty with backgrounds in
academia, industry, government and
several different disciplines,
allows students to hear a variety of
perspectives on the drug development
process," says Dr. Kevin Skare, a
former senior director of clinical
research for Procter & Gamble
Pharmaceuticals who now serves as a
faculty member of the drug
development program. "This expands
their horizons and stimulates
diverse thinking on various issues
and can lead to increased creativity
and product innovation."
In addition to the classroom
curriculum, the program offers
twice-quarterly seminars that cover
specialized topics from guest
lecturers in very narrow fields.
Representatives of Eli Lilly and
Company, Ethicon, Glaxo Smith Kline,
Pharmaceutical Product Development
Inc., Merck, Glinrex GmbH, Novartis
and the U.S. Food and Drug
Administration have each presented
lectures on topics related to the
pharmaceutical industry.
International speakers from
countries such as the Federal
Republic of Germany, United Kingdom
and India have also participated in
the seminar series.
Students are also required to give a
seminar in the first summer, based
on their areas of expertise or
interest. Because students have a
variety of academic degrees, from
bachelor degrees and MBAs to PhDs,
the student-presented seminars
demonstrate the diversity of each
student's interests.
The program concludes with a
detailed capstone project that
students work on for the entirety of
their second year. Students are
encouraged to choose a topic of
their interest, based on the
direction they'd like their career
to take. Examples have included
lessons learned from costly drug
failures such as Vioxx, the impact
of genomics on clinical trials/drug
development and the benefits and
pitfalls of global clinical trials.
To date, 36 students have
successfully completed the entire
program, while 20 students are
currently enrolled. Each gives a
glowing review of the drug
development program.
Take Brenna Carey, PhD, who works
full time at Cincinnati Children's
Hospital Medical Center in pulmonary
biology and neonatology. "Because of
this program, I see myself
transitioning from a basic scientist
to more of a translational
scientist," says Carey. "The program
has also given me a better
understanding of the drug
development process and government
regulations."
Desai hopes to expand enrollment
with the launch of a distance
learning curriculum in the fall of
2010. The expansion would enable
people from throughout the world to
enroll in the master's program.
Though the program was started with
seed money from Kendle
International, demand has quickly
exceeded the university's available
resources.
"Unfortunately, adding a distance
learning complement requires
funding," he said. "We're currently
in the process of identifying
pharmaceutical and research
companies that may be willing to
underwrite the cost of expanding the
program, given the potential impact
a master's program like this one
could have on the industry. The
University of Cincinnati Foundation
has been a great resource in helping
us identify potential sources, but
there is still work to be done."
Desai said the popularity of the
program will only continue to
increase as professionals seek
opportunities to differentiate
themselves from their competition
and big pharmaceutical companies
look to operating more efficiently
on a global scale.
"There is a significant need for
this program, especially as drug
companies face more pressure to do
their work effectively and speak a
global language," says Desai.
Ranked by the National Science
Foundation among the top 20 public
research universities in the United
States, UC's faculty have
distinguished themselves worldwide
for their creative teaching and
research. The University of
Cincinnati serves a diverse
enrollment of more than 39,000.
04/04/10
Site Map | Contact Us
|